Skip to Content
Merck
  • Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation.

Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation.

Journal of neurology, neurosurgery, and psychiatry (2013-11-13)
Yo-Tsen Liu, Joshua Hersheson, Vincent Plagnol, Katherine Fawcett, Kate E C Duberley, Elisavet Preza, Iain P Hargreaves, Annapurna Chalasani, Matilde Laurá, Nick W Wood, Mary M Reilly, Henry Houlden
ABSTRACT

The autosomal-recessive cerebellar ataxias (ARCA) are a clinically and genetically heterogeneous group of neurodegenerative disorders. The large number of ARCA genes leads to delay and difficulties obtaining an exact diagnosis in many patients and families. Ubiquinone (CoQ10) deficiency is one of the potentially treatable causes of ARCAs as some patients respond to CoQ10 supplementation. The AarF domain containing kinase 3 gene (ADCK3) is one of several genes associated with CoQ10 deficiency. ADCK3 encodes a mitochondrial protein which functions as an electron-transfer membrane protein complex in the mitochondrial respiratory chain (MRC). We report two siblings from a consanguineous Pakistani family who presented with cerebellar ataxia and severe myoclonus from adolescence. Whole exome sequencing and biochemical assessment of fibroblasts were performed in the index patient. A novel homozygous frameshift mutation in ADCK3 (p.Ser616Leufs*114), was identified in both siblings. This frameshift mutation results in the loss of the stop codon, extending the coding protein by 81 amino acids. Significant CoQ10 deficiency and reduced MRC enzyme activities in the index patient's fibroblasts suggested that the mutant protein may reduce the efficiency of mitochondrial electron transfer. CoQ10 supplementation was initiated following these genetic and biochemical analyses. She gained substantial improvement in myoclonic movements, ataxic gait and dysarthric speech after treatment. This study highlights the importance of diagnosing ADCK3 mutations and the potential benefit of treatment for patients. The identification of this new mutation broadens the phenotypic spectrum associated with ADCK3 mutations and provides further understanding of their pathogenic mechanism.

MATERIALS
Product Number
Brand
Product Description

USP
Ubidecarenone for System Suitability, United States Pharmacopeia (USP) Reference Standard
USP
Ubidecarenone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Coenzyme Q10, ≥98% (HPLC)
Ubidecarenone for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Coenzyme Q10, analytical standard
Ubidecarenone, European Pharmacopoeia (EP) Reference Standard